DoD Peer Reviewed Orthopaedic Clinical Trial Award | Apply Online

Frequently Asked Questions (FAQs)

What is the PRORP Clinical Trial Award?

The DoD Peer Reviewed Orthopaedic Clinical Trial Award (PRORP Clinical Trial Award) is a Department of the Army funding opportunity managed through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It supports clinical trials intended to move quickly into implementation and generate real-world evidence that could change care for combat-relevant orthopaedic injuries.

Which federal program and CFDA number is this opportunity under?

This opportunity is managed under CFDA 12.420, Military Medical Research and Development.

Who manages the award?

The opportunity is managed through the U.S. Army Medical Research Acquisition Activity (USAMRAA) as a Department of the Army funding opportunity.

What is the main purpose of this award?

The main purpose is to rapidly implement orthopaedic clinical trials that can produce near-term clinical impact and meaningful improvements in care for Service members and Veterans with musculoskeletal injuries linked to military service, particularly injuries associated with combat or combat-like conditions.

What kinds of studies does this program want to fund?

The program is focused on clinical trials that are ready to be put into action quickly, with an emphasis on producing real-world evidence and outcomes that could meaningfully change clinical care for combat-relevant orthopaedic injuries.

What types of interventions can be evaluated in proposed clinical trials?

The scope is broad as long as it fits the orthopaedic and combat-relevance mission. Trials may evaluate promising medical products, pharmacologic agents (including drugs and biologics), medical devices, clinical guidance or protocols, and emerging approaches or technologies aimed at improving outcomes in orthopaedic injury care.

Is early-stage exploratory research appropriate for this award?

The emphasis is on interventions that are ready for clinical testing rather than early-stage exploratory research, because the award is intended to support rapid trial implementation.

What does "combat-relevant orthopaedic injuries" mean in the context of this opportunity?

In this opportunity, combat relevance refers to musculoskeletal injuries linked to military service, especially those associated with combat or combat-like conditions, and to studies that could meaningfully change care for those injury types.

How important is military relevance in the application?

Military relevance is a central requirement. Every application must provide a strong, well-argued justification explaining how the proposed trial addresses the needs of military and/or Veteran populations affected by combat-relevant orthopaedic injury.

Are collaborations with military researchers or clinicians encouraged?

Yes. The program encourages collaboration with military researchers and clinicians and shows a preference for projects connected to military medical settings and operational realities.

Does the program prioritize studies that enroll active duty Service members or Veterans?

Yes. During programmatic review, studies that include active duty military personnel or Veteran participants (either as the full study population or as a defined subset) are expected to receive higher priority for funding.

Can a trial that uses only civilian participants be competitive?

The opportunity indicates that trials directly enrolling active duty military personnel or Veterans are positioned more favorably. A trial relying only on civilian cohorts would need a convincing bridge to military needs, since military relevance is required and direct enrollment of the target populations is expected to be prioritized.

When was this funding opportunity posted?

The opportunity was posted on May 15, 2012.

What were the application closing dates?

The original and final application closing date listed is September 25, 2012.

When was the opportunity archived?

The archive date listed is October 25, 2012.

How much funding is estimated to be available?

The estimated total funding amount listed is $16,000,000.

How many awards were anticipated?

The opportunity lists an anticipated four awards.

What type of funding instrument is used?

The funding instrument is listed as a cooperative agreement and/or grant.

What funding category does this opportunity fall under?

The category is listed as science and technology and other research and development.

Is cost sharing or matching required?

No. The opportunity states there is no cost sharing or matching requirement.

Who is eligible to apply?

Eligibility is described as unrestricted, meaning it is broadly open to a wide range of applicant organizations, subject to any clarifications that may appear in the full announcement.

Where can applicants get help with the full announcement or submission issues?

Support is available through the CDMRP Help Desk at 301-682-5507 or by email at help@cdmrp.org.

What is the overall emphasis of this award compared to other research programs?

The stated emphasis is on quickly launching clinical trials with interventions ready for clinical testing, producing real-world evidence, and delivering near-term clinical impact for combat-relevant orthopaedic injury care in Service member and Veteran populations.